Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 16 that BIOA announced the dosing of the first participant in QUELL-CV, a Phase 2 proof-of-concept study evaluating BGE-102. The investigational therapy is a potent, orally available, brain-penetrant small molecule NLRP3 inhibitor designed for once-daily administration. BIOA is developing BGE-102 with cardiovascular risk reduction as its lead therapeutic focus. The initiation of the QUELL-CV trial represents progress in advancing the company’s clinical program targeting cardiovascular disease pathways.

Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?

BioAge Labs, Inc. (NASDAQ:BIOA) previously reported its first quarter 2026 financial results on May 8, highlighting the continued advancement of its therapeutic programs focused on cardiometabolic diseases and aging biology. The company shared progress from its BGE-102 program, where Phase 1 data showed strong reductions in hsCRP levels, including median decreases of 86% from baseline across evaluated dose groups. BGE-102 was well tolerated with no serious adverse events reported. BIOA plans to begin a Phase 2 dose-ranging study in participants with elevated cardiovascular risk in mid-2026. During the quarter, collaboration revenue reached $2.8 million, while research and development expenses increased to $20.4 million. As of March 31, 2026, BIOA held approximately $384.9 million in cash, cash equivalents, and marketable securities.

BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company using AI and longevity research to develop therapies targeting aging-related metabolic and cardiovascular diseases.

While we acknowledge the risk and potential of BIOA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BIOA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1